Search

Your search keyword '"Yurdaydin C"' showing total 565 results
Start Over Author "Yurdaydin C"
565 results on '"Yurdaydin C"'

51. The prenylation inhibitor lonafarnib can induce post-treatment viral clearance in patients with chronic delta hepatitis resulting in alt normalization and regression of fibrosis

Author

Yurdaydin, C., primary, Idilman, R., additional, Kalkan, C., additional, Karakaya, M.F., additional, Caliskan, A., additional, Keskin, O., additional, Yurdcu, E., additional, Karatayli, S.C., additional, Bozdayi, M., additional, Koh, C., additional, Heller, T., additional, and Glenn, J., additional

Published
2017
Full Text
View/download PDF

54. A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—end of treatment results from the LOWR HDV-2 study

Author

Yurdaydin, C., primary, Idilman, R., additional, Keskin, O., additional, Kalkan, C., additional, Karakaya, M.F., additional, Caliskan, A., additional, Yurdcu, E., additional, Karatayli, S.C., additional, Bozdayi, M., additional, Koh, C., additional, Heller, T., additional, and Glenn, J., additional

Published
2017
Full Text
View/download PDF

55. Diversity of clinical presentation and virological characteristics of hepatitis delta: The hepatitis Delta International network (HDIN)

Author

Wranke, A, additional, Hardtke, S, additional, Borzacov, LMP, additional, Parana, R, additional, Lobato, C, additional, Hamid, S, additional, Ceausu, E, additional, Dalekos, GN, additional, Rizzetto, M, additional, Turcanu, A, additional, Niro, G, additional, Ingiliz, P, additional, Muche, M, additional, Buti, M, additional, Ferenci, P, additional, Vanwolleghem, T, additional, Motoc, A, additional, Serrano, BC, additional, Wöbse, M, additional, Abbas, Z, additional, Yurdaydin, C, additional, Manns, MP, additional, and Wedemeyer, H, additional

Published
2016
Full Text
View/download PDF

60. INTERFERON TREATMENT OF DELTA HEPATITIS: THE LONGER THE DURATION THE BETTER THE SUCCESS?

Author

Kabacam, G., Yakut, M., Seven, GÜLSEREN, Bozkaya, H., Idilman, R., Yurdaydin, C., and SEVEN, GÜLSEREN

Subjects
THE LONGER THE DURATION THE BETTER THE SUCCESS?-, 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Berlin, Almanya, 01 Ocak 2011, cilt.54 [Kabacam G., Yakut M., Seven G., Bozkaya H., Idilman R., Yurdaydin C., -INTERFERON TREATMENT OF DELTA HEPATITIS]
Published
2011

61. CHARACTERIZATION OF THE INACTIVE HBSAG CARRIER STATE WITH 3 YEAR FOLLOW-UP

Author

Yakut, M., Bektas, M., Seven, GÜLSEREN, Kabacam, G., Karatayli, E., Karatayli, S., Bozdayi, A. M., Idilman, R., Yurdaydin, C., and SEVEN, GÜLSEREN

Subjects
Yakut M., Bektas M., Seven G., Kabacam G., Karatayli E., Karatayli S., Bozdayi A. M. , Idilman R., Yurdaydin C., -CHARACTERIZATION OF THE INACTIVE HBSAG CARRIER STATE WITH 3 YEAR FOLLOW-UP-, 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Berlin, Almanya, 01 Ocak 2011, cilt.54
Published
2011

62. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

Author

Cornberg, M, Razavi, Ha, Alberti, Alfredo, Bernasconi, E, Buti, M, Cooper, C, Dalgard, O, Dillion, Jf, Flisiak, R, Forns, X, Frankova, S, Goldis, A, Goulis, I, Halota, W, Hunyady, B, Lagging, M, Largen, A, Makara, M, Manolakopoulos, S, Marcellin, P, Marinho, Rt, Pol, S, Poynard, T, Puoti, M, Sagalova, O, Sibbel, S, Simon, K, Wallace, C, Young, K, Yurdaydin, C, Zuckerman, E, Negro, F, and Zeuzem, S.

Subjects
ddc:616, Canada, Time Factors, Genotype, Incidence, Canada/epidemiology, Hepacivirus/genetics, Hepacivirus, ddc:616.07, Hepatitis C, Risk Assessment, Europe/epidemiology, Europe, Hepatitis C/diagnosis/epidemiology/prevention & control/therapy/transmission, Risk Factors, Prevalence, Humans, Israel, Epidemics, Israel/epidemiology
Abstract

Decisions on public health issues are dependent on reliable epidemiological data. A comprehensive review of the literature was used to gather country-specific data on risk factors, prevalence, number of diagnosed individuals and genotype distribution of the hepatitis C virus (HCV) infection in selected European countries, Canada and Israel.Data references were identified through indexed journals and non-indexed sources. In this work, 13,000 articles were reviewed and 860 were selected based on their relevance.Differences in prevalence were explained by local and regional variances in transmission routes or different public health measures. The lowest HCV prevalence (≤ 0.5%) estimates were from northern European countries and the highest (≥ 3%) were from Romania and rural areas in Greece, Italy and Russia. The main risk for HCV transmission in countries with well-established HCV screening programmes and lower HCV prevalence was injection drug use, which was associated with younger age at the time of infection and a higher infection rate among males. In other regions, contaminated glass syringes and nosocomial infections continue to play an important role in new infections. Immigration from endemic countries was another factor impacting the total number of infections and the genotype distribution. Approximately 70% of cases in Israel, 37% in Germany and 33% in Switzerland were not born in the country. In summary, HCV epidemiology shows a high variability across Europe, Canada and Israel.Despite the eradication of transmission by blood products, HCV infection continues to be one of the leading blood-borne infections in the region.

Published
2011

66. Hepatitis Delta Virus Kinetics under the Prenylation Inhibitor Lonafarnib Suggest HDV-Mediated Suppression of HBV Replication

Author

Yurdaydin, C., primary, Borochov, N., additional, Kalkan, C., additional, DebRoy, S., additional, Karatayli, E., additional, Haynes-Williams, V., additional, Karatayli, S.C., additional, Canini, L., additional, Uprichard, S.L., additional, Bozdayi, A. Mihat, additional, Choong, I., additional, Cory, D., additional, Heller, T., additional, Cotler, S., additional, Idilman, R., additional, Glenn, J.S., additional, and Dahari, H., additional

Published
2016
Full Text
View/download PDF

67. Dose-dependent decrease in hepatitis delta virus (HDV) RNA achieved with the oral prenylation inhibitor lonafarnib in a proof-of-concept, randomised, double-blinded, placebo-controlled study in patients with chronic HDV infection

Author

Koh, C., primary, Canini, L., additional, Dahari, H., additional, Cooper, S., additional, Cory, D., additional, Winters, M.A., additional, Choong, I., additional, Cotler, S.J., additional, Kleiner, D.E., additional, Yurdaydin, C., additional, Heller, T., additional, and Glenn, J.S., additional

Published
2015
Full Text
View/download PDF

68. P0641 : Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the impact of hepatocellular carcinoma (HCC)

Author

Papatheodoridis, G., primary, Dalekos, G., additional, Yurdaydin, C., additional, Buti, M., additional, Sypsa, V., additional, Goulis, J., additional, Calleja, J.L, additional, Chi, H., additional, Manolakopoulos, S., additional, Mangia, G., additional, Gatselis, N., additional, Keskın, O., additional, Savvidou, S., additional, De La Revilla, J., additional, Hansen, B.E., additional, Vlachogiannakos, I., additional, Galanis, K., additional, Idılman, R., additional, Colombo, M., additional, Esteban, R., additional, Janssen, H.L., additional, and Lampertico, P., additional

Published
2015
Full Text
View/download PDF

72. P0638 : Global epidemiology of hepatitis delta: First data from the hepatitis delta international network

Author

Hardtke, S., primary, Abbas, Z., additional, Hamid, S., additional, Ceausu, E., additional, Dalekos, G.N., additional, Niro, G., additional, Corti, G., additional, Pinheiro Borzacov, L.M., additional, Parana, R., additional, Gatselis, N.K., additional, Motoc, A., additional, Ingiliz, P., additional, Muche, M., additional, Wranke, A., additional, Wöbse, M., additional, Yurdaydin, C., additional, Manns, M.P., additional, and Wedemeyer, H., additional

Published
2015
Full Text
View/download PDF

73. LP36 : Understanding hepatitis delta virus and HBsAG kinetics during treatment with prenylation inhibitor lonafarnib via mathematical modeling

Author

Canini, L., primary, Koh, C., additional, Cotler, S.J., additional, Zhao, X., additional, Uprichard, S.L., additional, Haynes-Williams, V., additional, Winters, M.A., additional, Subramanya, G., additional, Cooper, S.L., additional, Pinto, P., additional, Wolff, E., additional, Bishop, R., additional, Than Han, M.A., additional, Kleiner, D.E., additional, Keskin, O., additional, Idilman, R., additional, Yurdaydin, C., additional, Glenn, J.S., additional, Heller, T., additional, and Dahari, H., additional

Published
2015
Full Text
View/download PDF

74. OUTCOME AND VIROLOGICAL CHANGES DURING THE FOLLOW UP OF A LARGE SINGLE CENTER COHORT OF CHRONIC DELTA HEPATITIS PATIENTS

Author

Kabacam, G., Oender, F. O., Seven, GÜLSEREN, Yakut, M., Bozkaya, H., Bozdayi, M. A., Idilman, R., Yurdaydin, C., and SEVEN, GÜLSEREN

Subjects
Kabacam G., Oender F. O. , Seven G., Yakut M., Bozkaya H., Bozdayi M. A. , Idilman R., Yurdaydin C., -OUTCOME AND VIROLOGICAL CHANGES DURING THE FOLLOW UP OF A LARGE SINGLE CENTER COHORT OF CHRONIC DELTA HEPATITIS PATIENTS-, 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Vienna, Avusturya, 14 - 18 Nisan 2010, cilt.52
Published
2010

86. THU-157 - Diversity of clinical presentation and virological characteristics of hepatitis delta in different regions world-wide: results of the Hepatitis Delta International network

Author

Wranke, A., Hardtke, S., Borzacov, L.M.P., Parana, R., Lobato, C., Hamid, S., Ceausu, E., Dalekos, G.N., Rizzetto, M., Turcanu, A., Niro, G., Hayden, T., Abbas, M., Ingiliz, P., Buti, M., Ferenci, P., Vanwolleghem, T., Motoc, A., Abbas, Z., Yurdaydin, C., Manns, M.P., Wedemeyer, H., Serrano, B.C., Wöbse, M., Heidrich, B., Muche, M., Gatselis, N.K., Zachou, K., Smedile, A., Gish, R., Obretin, D., Stern, R., Ho, E., Michielsen, P., Valentina, O.D., Lubna, F., and Fontana, R.

Published
2017
Full Text
View/download PDF

89. O4 PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED-INTERFERON-α-2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDVRNA RELAPSE AFTER TREATMENT: THE HIDIT-2 STUDY

Author

Wedemeyer, H., primary, Yurdaydin, C., additional, Ernst, S., additional, Caruntu, F.A., additional, Curescu, M.G., additional, Yalcin, K., additional, Akarca, U.S., additional, Gürel, S., additional, Zeuzem, S., additional, Erhardt, A., additional, Lüth, S., additional, Papatheodoridis, G.V., additional, Keskin, O., additional, Port, K., additional, Radu, M., additional, Celen, M.K., additional, Ildeman, R., additional, Stift, J., additional, Heidrich, B., additional, Mederacke, I., additional, Hardtke, S., additional, Koch, A., additional, Dienes, H.P., additional, and Manns, M.P., additional

Published
2014
Full Text
View/download PDF

91. P1075 PAGE-B: RISK SCORE FOR HEPATOCELLULAR CARCINOMA (HCC) DEVELOPMENT IN CAUCASIAN CHRONIC HEPATITIS B (CHB) PATIENTS RECEIVING ENTECAVIR (ETV) OR TENOFOVIR (TDF)

Author

Papatheodoridis, G.V., primary, Dalekos, G., additional, Sypsa, V., additional, Yurdaydin, C., additional, Buti, M., additional, Goulis, J., additional, Arends, P., additional, Manolakopoulos, S., additional, Mangia, G., additional, Gatselis, N., additional, Keskın, O., additional, Savvidou, S., additional, Hansen, B.E., additional, Papaioannou, C., additional, Galanis, K., additional, Idılman, R., additional, Colombo, M., additional, Esteban, R., additional, Janssen, H.L.A., additional, and Lampertico, P., additional

Published
2014
Full Text
View/download PDF

93. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version)

Author

Franchis, R., Hadengue, A., Lau, G., Lavanchy, D., Lok, A., Mcintyre, N., Mele, A., Paumgartner, G., Pietrangelo, A., Rodés, J., Rosenberg, W., Valla, D., Alberti, A., Dusheiko, G., Hadziyannis, S., Marcellin, P., Rizzetto, M., Samuel, D., Shouval, D., Alter, M., Benhamou, Y., Bonanni, P., Bonino, F., Bortolotti, F., Jordi Bruix, Brunetto, M., Colombo, M., Cooksley, G., Craxi, A., Desmet, V., Duclos, P., Esteban, R., Farci, P., Fattovich, G., Ferrari, C., Heathcote, J., Hoofnagle, J., Liaw, Y. -F, Locarnini, S., Manns, M., Namgyal, P., Naoumov, N., Pawlotsky, J. -M, Perrillo, R., Pol, S., Pontisso, P., Raimondo, G., Roggendorf, M., Schalm, S., Thomas, H., Trépo, C., Damme, P., Will, H., Wright, T., Zeuzem, S., Zoulim, F., Day, C., Levrero, M., Nevens, F., and Yurdaydin, C.

Subjects
SURFACE-ANTIGEN, E-ANTIGEN SEROCONVERSION, Patient Selection, LAMIVUDINE THERAPY, INTERFERON-ALFA, ADEFOVIR DIPIVOXIL ADV, TERM FOLLOW-UP, VIRUS-INFECTION, NATURAL-HISTORY, Hepatitis B, LIVER-DISEASE, Population Surveillance, Humans, Patient Selection, Population Surveillance, Preventive Medicine, Public Health, CIRRHOSIS TYPE-B, Humans, Preventive Medicine, Public Health
Published
2003

94. ANTI-HDV-IgM AS A MARKER OF DISEASE ACTIVITY IN HEPATITIS DELTA

Author

Wranke, A. Yurdaydin, C. Heidrich, B. Caruntu, F. A. and Curescu, M. G. Yalcin, K. Gurel, S. Zeuzem, S. Erhardt, A. Lueth, S. Papatheodoridis, G. V. Bremer, B. Stift, J. and Grabowski, J. Kirschner, J. Port, K. Cornberg, M. and Falk, C. Dienes, H. P. Hardtke, S. Manns, M. P. and Wedemeyer, H. HIDIT-2 Study Grp and Wranke, A. Yurdaydin, C. Heidrich, B. Caruntu, F. A. and Curescu, M. G. Yalcin, K. Gurel, S. Zeuzem, S. Erhardt, A. Lueth, S. Papatheodoridis, G. V. Bremer, B. Stift, J. and Grabowski, J. Kirschner, J. Port, K. Cornberg, M. and Falk, C. Dienes, H. P. Hardtke, S. Manns, M. P. and Wedemeyer, H. HIDIT-2 Study Grp

Published
2013

96. Risk factors for hepatocellular carcinoma in Turkey

Author

Sarioglu, M, Tankurt, E, Colakoglu, S, Sahin, T, Bozkaya, H, Yurdaydin, C, Uzunalimoglu, O, Cetinkaya, H, Okten, A, Degertekin, H, Tozun, N, Akkiz, H, and Ozenirler, S

Abstract

The contribution of hepatitis B, hepatitis C, and excess alcohol intake to the development of hepatocellular carcinoma in Turkey was assessed. The study was conducted through a questionnaire sent to seven major medical referral centers in different regions of Turkey and is based on 207 patients seen in the period 1994-1997. Of the seven centers, two were located in West Turkey (54 patients), two were in Central Turkey (85 patients), and two were in south and southeast Turkey (68 patients). In 196 of the 207 patients (94.7%), there was a history of chronic liver disease, and in 180 patients (87%) liver cirrhosis was documented, Of the 207 patients, 116 (56%) had hepatitis B, 48 (23.2%) had hepatitis C and 33 (15.9%) had a history of excess alcohol intake. Anti-delta testing was available in 69 of 116 patients with hepatitis B, and anti-HDV was positive in 13 of these patients (13/69, 18.8%). Of the 33 patients with a history of heavy alcohol intake, 18 had concomitant chronic viral hepatitis infection, and alcohol alone was the etiology of hepatocellular carcinoma in only 15 cases (7.2%). The distribution of etiologic factors was not homogenous in different geographical regions ill Turkey. In central, south, and southeastern Turkey, the predominant etiology of hepatocellular carcinoma was hepatitis B, whereas in western Turkey the impact of hepatitis B, hepatitis C, and alcohol was similar. This study indicates that hepatitis B virus infection is the leading cause of hepatocellular carcinoma in Turkey, followed by hepatitis C infection and alcoholic liver disease.

Published
2001

97. Risk factors for hepatocellular carcinoma in turkey

Author

Uzunalimoglu Ö., Yurdaydin C., Çetinkaya H., Bozkaya H., Şahin T., Çolakoglu S., Tankurt E., and Çukurova Üniversitesi

Subjects
Turkey, Hepatocellular carcinoma, Alcohol, Hepatitis B, Hepatitis C
Abstract

PubMedID: 11341644 The contribution of hepatitis B, hepatitis C, and excess alcohol intake to the development of hepatocellular carcinoma in Turkey was assessed. The study was conducted through a questionnaire sent to seven major medical referral centers in different regions of Turkey and is based on 207 patients seen in the period 1994-1997. Of the seven centers, two were located in West Turkey (54 patients), two were in Central Turkey (85 patients), and two were in south and southeast Turkey (68 patients). In 196 of the 207 patients (94.7%), there was a history of chronic liver disease, and in 180 patients (87%) liver cirrhosis was documented. Of the 207 patients, 116 (56%) had hepatitis B, 48 (23.2%) had hepatitis C, and 33 (15.9%) had a history of excess alcohol intake. Anti-delta testing was available in 69 of 116 patients with hepatitis B, and anti-HDV was positive in 13 of these patients (13/69, 18.8%). Of the 33 patients with a history of heavy alcohol intake, 18 had concomitant chronic viral hepatitis infection, and alcohol alone was the etiology of hepatocellular carcinoma in only 15 cases (7.2%). The distribution of etiologic factors was not homogenous in different geographical regions in Turkey. In central, south, and southeastern Turkey, the predominant etiology of hepatocellular carcinoma was hepatitis B, whereas in western Turkey the impact of hepatitis B, hepatitis C, and alcohol was similar. This study indicates that hepatitis B virus infection is the leading cause of hepatocellular carcinoma in Turkey, followed by hepatitis C infection and alcoholic liver disease.

Published
2001

98. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country

Author

Toy, M. (Mehlika), Onder, G. (Graziano), Idilman, R. (Ramazan), Kabacam, G. (Gokhan), Richardus, J.H. (Jan Hendrik), Bozdayi, A.M. (Mithat), Akdogan, M. (Meral), Kuloglu, Z. (Zarife), Kansu, A. (Aydan), Schalm, S.W. (Solko), Yurdaydin, C. (Cihan), Toy, M. (Mehlika), Onder, G. (Graziano), Idilman, R. (Ramazan), Kabacam, G. (Gokhan), Richardus, J.H. (Jan Hendrik), Bozdayi, A.M. (Mithat), Akdogan, M. (Meral), Kuloglu, Z. (Zarife), Kansu, A. (Aydan), Schalm, S.W. (Solko), and Yurdaydin, C. (Cihan)

Abstract

Background/aims: Chronic hepatitis B (CHB) infection is a serious public health problem due to its potential liver disease sequelae and highly expensive medical costs such as the need for liver transplantation. The aim of this study was to quantify the burden of active CHB in terms of mortality and morbidity, the eligibility of antiviral treatment and to assess various treatment scenarios and possible salvage combinations for cost-effectiveness. Methods: A population cohort from a large data base of chronic hepatitis B patients was constructed and stratified according to 10-year age groups, the prevalence of HBsAg, HBV DNA level, ALT level, HBeAg status and the presence of cirrhosis. An age-specific Markov model for disease progression and cost-effectiveness analysis was constructed and calibrated for the specific population setting. Results: Of about 3.2 million estimated HBsAg carriers, 25 % are eligible for treatment. If the active cohort remains untreated, 31 % will die due to liver related complications. Within a 20-year period, 11 % will have developed decompensated cirrhosis, 12 % liver cancer and 6 % will need liver transplantation. Quality adjusted life years (QALYs) for the no treatment scenario ranged from 9.3 to 14.0. For scenarios with antiviral treatment, QALYs ranged from 9.9 to 14.5 for lamivudine, 13.0-17.5 for salvage therapy, and 16.6-19.0 for the third generation drugs entecavir and tenofovir. Conclusion: In a country with considerable amount of active CHB patients, monotherapy with a highly potent third generation drug has the most health-gain, and is cost-effective in both HBeAg-positive and negative in all stages of liver disease.

Published
2012
Full Text
View/download PDF

99. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country

Author

Toy, Mehlika, Onder, FO, Idilman, R, Kabacam, G, Richardus, Jan hendrik, Bozdayi, M, Akdogan, M, Kuloglu, Z, Kansu, A, Schalm, S, Yurdaydin, C, Toy, Mehlika, Onder, FO, Idilman, R, Kabacam, G, Richardus, Jan hendrik, Bozdayi, M, Akdogan, M, Kuloglu, Z, Kansu, A, Schalm, S, and Yurdaydin, C

Abstract

Chronic hepatitis B (CHB) infection is a serious public health problem due to its potential liver disease sequelae and highly expensive medical costs such as the need for liver transplantation. The aim of this study was to quantify the burden of active CHB in terms of mortality and morbidity, the eligibility of antiviral treatment and to assess various treatment scenarios and possible salvage combinations for cost-effectiveness. A population cohort from a large data base of chronic hepatitis B patients was constructed and stratified according to 10-year age groups, the prevalence of HBsAg, HBV DNA level, ALT level, HBeAg status and the presence of cirrhosis. An age-specific Markov model for disease progression and cost-effectiveness analysis was constructed and calibrated for the specific population setting. Of about 3.2 million estimated HBsAg carriers, 25 % are eligible for treatment. If the active cohort remains untreated, 31 % will die due to liver related complications. Within a 20-year period, 11 % will have developed decompensated cirrhosis, 12 % liver cancer and 6 % will need liver transplantation. Quality adjusted life years (QALYs) for the no treatment scenario ranged from 9.3 to 14.0. For scenarios with antiviral treatment, QALYs ranged from 9.9 to 14.5 for lamivudine, 13.0-17.5 for salva In a country with considerable amount of active CHB patients, monotherapy with a highly potent third generation drug has the most health-gain, and is cost-effective in both HBeAg-positive and negative in all stages of liver disease.

Published
2012

100. Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: A systematic review

Author

Toy, M. (Mehlika), Önder, F.O. (Fatih), Wörmann, T. (Tanja), Bozdayi, A.M. (Mithat), Schalm, S.W. (Solko), Borsboom, G.J.J.M. (Gerard), Rosmalen, J.M. (Joost) van, Richardus, J.H. (Jan Hendrik), Yurdaydin, C. (Cihan), Toy, M. (Mehlika), Önder, F.O. (Fatih), Wörmann, T. (Tanja), Bozdayi, A.M. (Mithat), Schalm, S.W. (Solko), Borsboom, G.J.J.M. (Gerard), Rosmalen, J.M. (Joost) van, Richardus, J.H. (Jan Hendrik), and Yurdaydin, C. (Cihan)

Abstract

Background: To provide a clear picture of the current hepatitis B situation, the authors performed a systematic review to estimate the age- and region-specific prevalence of chronic hepatitis B (CHB) in Turkey.Methods: A total of 339 studies with original data on the prevalence of hepatitis B surface antigen (HBsAg) in Turkey and published between 1999 and 2009 were identified through a search of electronic databases, by reviewing citations, and by writing to authors. After a critical assessment, the authors included 129 studies, divided into categories: 'age-specific'; 'region-specific'; and 'specific population group'. To account for the differences among the studies, a generalized linear mixed model was used to estimate the overall prevalence across all age groups and regions. For specific population groups, the authors calculated the weighted mean prevalence.Results: The estimated overall population prevalence was 4.57, 95% confidence interval (CI): 3.58, 5.76, and the estimated total number of CHB cases was about 3.3 million. The outcomes of the age-specific groups varied from 2.84, (95% CI: 2.60, 3.10) for the 0-14-yearolds to 6.36 (95% CI: 5.83, 6.90) in the 25-34-year-old group.Conclusion: There are large age-group and regional differences in CHB prevalence in Turkey, where CHB remains a serious health problem.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results